Company / Operating Cash Flow
CRESCENT BIOPHARMA, INC. Operating Cash Flow History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$71.5M
FY2025
5-year range
-$71.5M / -$4.3M
FY2021-FY2025
Trend
-767.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow changed -768% YoY in FY2025, a notable deviation from the 4-year average annual change of -209%.
Based on SEC 10-K filings.
-$72M in FY2025.
Declined from -$4M to -$72M over the past 9 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 767.9% year-over-year.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$71.5M | -767.9% |
| FY2017 | -$8.2M | -92.5% |
| FY2016 | -$4.3M | +72.4% |
| FY2015 | -$15.5M | -48.4% |
| FY2014 | -$10.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026